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Key Points
• Serum levels of galectin-1 are
significantly higher in patients
with cHL than in normal
controls.
• Galectin-1 serum levels are
associated with clinical
parameters of tumor
burden in patients with
cHL.
Galectin-1 (Gal1) is amember of a highly conserved family of carbohydrate-binding proteins.
It modulates innate and adaptive immune responses and fosters tumor-immune escape.
Hodgkin lymphoma (HL) Reed-Sternberg cells overexpress and secrete Gal1, which
selectively kills T helper (Th)1 and Th17 cells and cytotoxic T cells and promotes the
immunosuppressive Th2/regulatory T-cell–predominant HL microenvironment. We devel-
oped a sandwich enzyme-linked immunosorbent assay and assessed serum Gal1 levels in
293 newly diagnosed, previously untreated patientswith classical HL (cHL) enrolled in 3 risk-
adapted clinical trials. SerumGal1 levelsweresignificantlyhigher in patientswith cHL than in
normal controls (P < .0001). Gal1 serum levels also increased with Ann Arbor stage (P 5
.012), areas of nodal involvement (P < .0001), and the International Prognostic Score (2-7,P5
.019).We conclude thatGal1 serum levels are significantly associatedwith tumorburden and
related clinical features in newly diagnosed cHL patients. (Blood. 2013;121(17):3431-3433)
Introduction
Galectin-1 (Gal1), a member of a highly conserved family of
carbohydrate-binding proteins, modulates immune responses and
fosters tumor-immune escape through speciﬁc recognition of N-
acetyllactosamine (Gal-b1-4-NAcGlc) residues on the branches of
N- or O-linked glycans.1-4 Although Gal1 induces apoptosis of T
helper (Th)1 and Th17 cells and cytotoxic T cells, Th2 cells resist
Gal1-induced cell death through differential sialylation of cell surface
glycoproteins.5 Gal1 also promotes the expansion of regulatory T
(Treg) cells,1,5 and Gal1-glycan interactions augment hypoxia-driven
tumor angiogenesis.6
Primary classical Hodgkin lymphomas (cHLs) include small
numbers of malignant Hodgkin Reed-Sternberg (HRS) cells within
a Th2/Treg-skewed inﬂammatory inﬁltrate.1,7 In previous studies, we
found that HRS cells overexpress Gal1, which selectively kills Th1
and cytotoxic T cells and promotes the immunosuppressive Th2/
Treg-predominant Hodgkin lymphoma (HL) microenvironment.1 In
cHLs, which exhibit constitutive activation of the activator protein 1
(AP-1) signaling pathway, Gal1 overexpression is driven in large part
by an AP-1–dependent enhancer.1,8 In recent immunohistochemical
analyses of primary cHLs, increased Gal1 expression was associated
with poorer event-free survival.9
Given the broadly immunosuppressive activities of Gal1, we
reasoned that this soluble lectin might be a potent marker of disease
activity and a novel therapeutic target in cHLs. We previously
developed a panel of Gal1 monoclonal antibodies (mAbs) and
demonstrated the utility of Gal1 as a diagnostic marker of AP-1–
dependent lymphoid malignancies.8,10 A potent neutralizing Gal1
mAb also protected Th1 and cytotoxic T cells from Gal1-induced
apoptosis,10 abrogated Gal1-associated tumor angiogenesis,6 and
limited the growth of Gal11 tumors in vivo.6
We have now used a newly developed sandwich enzyme-linked
immunosorbent assay (ELISA) to assess the utility of Gal1 as a
serum marker of disease burden in cHLs.
Study design
Patients and samples
For this retrospective study, we used frozen serum samples and clinical
data from 293 newly diagnosed, previously untreated patients with
cHL who were enrolled on Institutional Review Board–approved,
risk-adapted German Hodgkin Study Group (GHSG) multicenter
clinical trials: HD13 (ISRCTN63474366) for early-stage low-risk
disease (clinical stage [CS] IA-IIB with no risk factors, 80
patients)11,12; HD14 (ISRCTN04761296) for early-stage disease
with risk factors (CS I-IIA with large mediastinal mass, extranodal
disease, elevated erythrocyte sedimentation rate (ESR) or.3 nodal
areas and CS IIB with elevated ESR or .3 nodal areas, 89
patients)11,13; and HD18 (NCT00515554) for bulky localized or
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advanced-stage disease (CS IIB with bulky mediastinal involvement
and/or extranodal involvement and CS III or IV, 124 patients).11,14
In addition, serum samples from 15 healthy normal donors were
prepared by centrifuging clotted peripheral blood at 2500 rpm for
20 minutes. This study was conducted in accordance with the
Declaration of Helsinki.
Gal1 sandwich ELISA
An anti-Gal1 rabbit polyclonal antibody (capture antibody) and
a biotin-coupled murine mAb, 8A12 (detection antibody), were
generated in our laboratory8,10 and determined to have optimal
sensitivity and signal-to-noise ratio. Serum Gal1 levels were assessed
according to a standard sandwich ELISA protocol. In brief, 96-well
EIA/RIA microplates (Fisher Scientiﬁc, Pittsburgh, PA) were
precoated with capture antibody at 4 mg/mL (100 mL per well,
diluted in 0.05 mol/L carbonate-bicarbonate buffer) at 4°C overnight.
After 3 washes with phosphate-buffered saline/0.05% Tween 20
(Sigma-Aldrich, St. Louis, MO), the plate was treated with blocking
buffer (1% bovine serum albumin in phosphate-buffered saline/
0.05% Tween 20) at room temperature (RT) for 1 hour. Serum-free
conditioned media from a Gal11 HL line, L428, and a serum sample
from a healthy normal donor (ND#1) were used as controls in each
ELISA plate. All samples were diluted (serum samples, 1:16; L428
serum-free conditioned media, 1:32) and added in duplicates, and
then incubated at RT for 2 hours. After the incubation with the
detection antibody, biotinylated 8A12 (1:1000), at RT for 2 hours,
100 mL of strepavidin-horseradish peroxidase (1:15 000; Thermo
Scientiﬁc, Rockford, IL) was added for incubation at RT for 20
minutes. After 5 washes, the reaction was developed by 100 mL of 1-
Step Turbo TMB (Thermo Scientiﬁc) and stopped by 1mol/L sulfuric
acid. Absorbance at 450 and 570 nmwere determined in a SpectraMax
M3 Absorbance Microplate Reader (Molecular Devices Inc,
Sunnyvale, CA). A standard curve of recombinant His-tagged Gal1
(rGal1) at concentrations of 80 to 0.312 ng/mL with 1:2 serial
dilutions (9 points total) was generated and ﬁtted using a 4-parameter
nonlinear regression curve for each ELISA. Sample concentrations
were calculated by regression analysis using the standard curve.
Statistical analysis
Data analysis was carried out using SAS software version 9.2 (SAS
Institute Inc., Cary, NC). A receiver operating characteristic (ROC)
curve was plotted to determine the cutoff values for normal vs
elevated serum Gal1. Because of skewed distributions, nonparametric
analyses of serum Gal1 values were performed using the Wilcoxon
2-sample test or Kruskal-Wallis test for group comparisons.
Univariate analyses included Ann Arbor stage (I-IV), number of
involved nodal sites (>3), presence of B symptoms, extranodal
disease, and elevated ESR, all of which are well-established
parameters of HL tumor burden. Serum Gal1 levels were also
analyzed with respect to male sex, age of 45 years or older, stage
IV disease, low serum albumin, leukocytosis, and lymphocytopenia,
Figure 1. Gal1 serum levels in cHL patients. Gal1 serum levels were assessed
with a sandwich ELISA. (A) Gal1 levels in cHL patients and normal healthy donors
(93.0 6 56.5 ng/mL vs 36.9 6 7.8 ng/mL, P , .0001). (B) Gal1 levels in patients on
the risk-adapted clinical trials, HD13 (early-stage low-risk), HD14 (early-stage with
risk factors), or HD18 (bulky localized or advanced-stage disease). (C) Gal1 levels in
cHL patients with Ann Arbor stage I, II, III, or IV disease. Nominal P values are
presented.
Table 1. GHSG trials, cHL patient characteristics, and association
with serum Gal1 levels
Patients (%) Gal1 (ng/mL)* P value
All patients 293 (100) 93.0 6 56.5
Trial/risk group .0002
HD13/favorable 80 (27.3) 71.6 6 39.7
HD14/intermediate 89 (30.4) 97.4 6 54.3
HD18/unfavorable 124 (42.3) 103.7 6 63.4
Age NS
$45 y 65 (22.2) 62.8 6 43.0
,45 y 228 (77.8) 90.4 6 55.9
Gender NS
Male 156 (53.2) 92.8 6 57.1
Female 137 (46.8) 89.6 6 53.6
Histologic type NS
Nodular sclerosis 151 (51.5) 95.9 6 55.9
Mixed cellularity 64 (21.8) 96.2 6 60.9
Lymphocyte rich 12 (4.1) 79.1 6 43.3
Unclassified 66 (22.5) 76.7 6 43.8
Ann Arbor stage .012
I 32 (10.9) 72.7 6 42.0
II 151 (51.5) 88.9 6 53.7
III 53 (18.1) 96.5 6 45.8
IV 46 (15.7) 116.4 6 76.5
Unknown† 11 (3.8)
B symptoms .047
Absence 168 (57.3) 85.3 6 47.1
Presence 114 (38.9) 104.1 6 67.1
Unknown† 11 (3.8)
IPS .019
0 or 1 134 (45.7) 82.4 6 44.0
2-7 128 (43.7) 103.7 6 66.0
Unknown† 31 (10.6)
Individual IPS risk factors
Extranodal involvement (stage IV) .011
Absence 249 (85.0) 89.2 6 54.3
Presence 35 (11.9) 116.3 6 67.2
Unknown† 9 (3.1)
Lymphocyte count, ,600/mm3 or ,8% of total white-cell count .036
Absence 269 (91.8) 91.2 6 56.2
Presence 13 (4.4) 124.9 6 62.9
Unknown† 11 (3.8)
Additional prognostic factors
Number of involved lymph node sites $3 ,.0001
Absence 120 (41.0) 78.6 6 49.0
Presence 165 (56.3) 102.7 6 59.6
Unknown† 8 (2.7)
Elevated erythrocyte sedimentation rate (ESR) .007
Absence 148 (50.5) 82.1 6 45.3
Presence 134 (45.7) 104.1 6 65.6
Unknown† 11 (3.8)
Gal1 serum levels were from cHL patients enrolled on the GHSG risk-adapted
clinical trials, HD13, HD14, and HD18. Nominal P values are presented.
NS, not significant.
*Mean 6 SD.
†Patients with unknown values were excluded from the indicated univariate
analyses.
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because of the prognostic relevance of these factors in the Inter-
national Prognostic Score (IPS)15,16 for advanced-stage HL.
Nominal P values are presented.
Results and discussion
After establishing a sandwich ELISA with puriﬁed rGal1 and the
newly developed Gal1 antibodies, we assessed the levels of serum
Gal1 in 15 healthy, normal donors and 293 newly diagnosed,
previously untreated patients with cHL from the GHSG. Serum Gal1
levels were signiﬁcantly elevated in patients with cHL in comparison
with normal controls (P , .0001) (Figure 1A). By plotting a ROC
curve, we found that a cutoff value of 49.9 ng/mL distinguished the
Gal1 serum levels of patients with cHL from those of normal donors
with 100% speciﬁcity and 76.5% sensitivity, respectively (data not
shown). Patients enrolled on the HD13 trial (for early-stage, low-risk
disease), had signiﬁcantly lower Gal1 levels than patients on HD14
(for early-stage disease with additional risk factors) or HD18 (for
bulky localized or advanced-stage disease) (HD13 vs HD14 vs
HD18, P 5 .0002) (Figure 1B and Table 1).
We next evaluated the potential association of Gal1 serum levels
with Ann Arbor stage and B symptoms, 2 major determinants for
assigning HL patients to risk-adapted therapy.17 Gal1 levels increased
with Ann Arbor stage (I vs II vs III vs IV, P 5 .012, Figure 1C and
Table 1; I-II vs III-IV, P 5 .006, data not shown) and with B
symptoms (P 5 .047) (Table 1).
We also assessed the potential association of Gal1 levels with the
HL IPS using the accepted groupings of IPS 0/1 vs 2-7.15,16 Patients
with an IPS of 2-7 had signiﬁcantly higher Gal1 levels than patients
with an IPS of 0 or 1 (P5 .019) (Table 1). Increased Gal1 levels were
also associated with 2 of 7 individual IPS risk factors15,16: extranodal
involvement (stage IV disease, P 5 .011) and lymphocyte count
,600 per mm3 or ,8% of total white cell count (P 5 .036). Gal1
levels were also signiﬁcantly elevated in patients with cHL and 2
additional adverse prognostic factors18: >3 involved nodal sites
(P, .0001) and elevated ESR (P5 .007) (Table 1). Direct analyses
of the association between Gal1 serum levels and outcome await
completion of the ongoing HD18 clinical trial.14
In conclusion, Gal1 serum levels are elevated and associated with
clinical features reﬂective of increased tumor burden in newly
diagnosed cHL patients. Given the demonstrated role of Gal1 in
tumor-immune escape, angiogenesis, and metastasis, analyses of
circulating Gal1 levels may inform risk-adapted and targeted
treatment strategies for patients with cHL.
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